IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Galera Therapeutics Inc

CUSIP: 36338D908 | 3 institutional holders

Quarters

Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023
CompareDetailedHistoricalFundsOptionsShort Interest13D/13GPeersTargetingTrading SummaryProfile